Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
Pfizer Inc PFE
News
-
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Declares Second-Quarter 2024 Dividend
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
How a Biden-Trump rematch can keep healthcare ETFs afloat this election year
Thinking about trading options or stock in NVIDIA, Trump Media & Technology, Microsoft, Enterprise Products Partners, or Pfizer?
BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
BioNTech's stock sinks after earnings miss, as inventory writedowns weigh
Repeat & Correct: Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale — Update
Pfizer to Cut Stake in Haleon — Update
Pfizer to Cut Stake in Haleon to 24%
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Thinking about trading options or stock in Apple, Pfizer, Taiwan Semiconductor, Microsoft, or Novo Nordisk?
Pfizer Sees Positive Overall Survival in Phase 3 Trial of Adcetris in Blood Cancer